98%
921
2 minutes
20
G-protein-coupled receptors (GPCRs) receive signals from ligands with different efficacies, and transduce to heterotrimeric G-proteins to generate different degrees of physiological responses. Previous studies revealed how ligands with different efficacies activate GPCRs. Here, we investigate how a GPCR activates G-proteins upon binding ligands with different efficacies. We report the cryo-EM structures of β-adrenergic receptor (β-AR) in complex with Gs (GαGβGγ) and a partial agonist or a very weak partial agonist, and compare them to the β-AR-Gs structure in complex with a full agonist. Analyses reveal similar overall complex architecture, with local conformational differences. Cellular functional studies with mutations of β-AR residues show effects on the cellular signaling from β-AR to the cAMP response initiated by the three different ligands, with residue-specific functional differences. Biochemical investigations uncover that the intermediate state complex comprising β-AR and nucleotide-free Gs is more stable when binding a full agonist than a partial agonist. Molecular dynamics simulations support the local conformational flexibilities and different stabilities among the three complexes. These data provide insights into the ligand efficacy in the activation of GPCRs and G-proteins.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283524 | PMC |
http://dx.doi.org/10.1038/s41467-022-31823-1 | DOI Listing |
Eur J Med Chem
September 2025
State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, PR China. Electronic address:
The Werner syndrome RecQ helicase (WRN) has recently emerged as a novel synthetic lethality target for microsatellite instability-high (MSI-H) cancers. However, available WRN inhibitors or degraders is still lacking so far. Particularly, chemically designed probes capable of degrading WRN irrespective of microsatellite status remain unexplored.
View Article and Find Full Text PDFACS Nano
September 2025
School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
Although traditional immunogenic cell death (ICD) inducers generate vaccines (ISV) to potentiate antiprogrammed cell death ligand 1 (anti-PDL1) antibodies therapy, their efficacy remains limited. This limitation may be attributed to the physical barrier created by extracellular matrix (ECM) and immunosuppressive metabolic barrier mediated by adenosine. Here, we report an oncolytic polymer (OP), a well-designed ε-polylysine derivative with ICD-inducing capacity, which can simultaneously facilitate the release of endogenous ECM-degrading enzyme, Cathepsin B.
View Article and Find Full Text PDFChem Sci
August 2025
Frontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, State Key Laboratory of Synergistic Chem-Bio Synthesis, Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University Shanghai 200240 China
Adipic acid is an essential platform molecule for polymer production and is industrially manufactured by thermochemical oxidation of the cyclohexanone/cyclohexanol mixture (KA oil). Alternatively, electrifying provides a green and sustainable route to synthesizing adipic acid, but has been restricted by the low catalytic efficiency. Herein, we report that a nickel hydroxide electrocatalyst functionalized with 4,4'-bipyridine (Bipy-Ni(OH)) delivers a 3-fold greater productivity compared with that of pristine Ni(OH), achieving an excellent yield (90%) towards efficient adipic acid electrosynthesis.
View Article and Find Full Text PDFFront Pharmacol
August 2025
Department of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Glioma therapy faces substantial challenges primarily due to the restrictive nature of the blood-brain barrier (BBB), limiting effective drug penetration and reducing therapeutic efficacy. Recent advancements in novel drug delivery systems (DDS), including exosome-mediated carriers, drug conjugates, and ultrasound-assisted delivery, have demonstrated promising results in overcoming these limitations. Exosomes offer superior biocompatibility, efficient BBB crossing, and natural cellular targeting capabilities; drug conjugates enable highly selective drug delivery through tumor-specific ligands; and ultrasound-assisted systems transiently disrupt the BBB to permit greater drug entry.
View Article and Find Full Text PDFOncol Res
September 2025
Department of Pathology, Changzhi Medical College, Changzhi, 046000, China.
Objectives: Checkpoint inhibitors have significantly improved outcomes in a number of malignancies. To determine the most effective course of treatment for head and neck squamous cell carcinoma (HNSCC), this systematic review evaluated the efficacy of several therapeutic approaches based on immune checkpoint inhibitors (ICIs).
Methods: A comprehensive evaluation of the literature was conducted, looking at randomized controlled trials (RCTs) that were published in Embase, PubMed, and the Cochrane Central Register of Controlled Trials since database establishment.